The results also suggest that either targeting IL-17F or abrogating the activity of both cytokines, targeting their common downstream receptor IL-17RC, could be another therapeutic avenue to attenuate the severe outcomes of COVID-19. This evidence concerns the gene IL17F and COVID-19.